Metabolic Score for Visceral Fat (METS-VF), a novel estimator of intra-abdominal fat content and cardio-metabolic health
| Autor: | Daniel Elías-López, Tannia Viveros-Ruiz, Arsenio Vargas-Vázquez, Neftali Eduardo Antonio-Villa, Ernesto Roldan-Valadez, Donaji V. Gómez-Velasco, Alexandro J. Martagón, Carlos A. Aguilar-Salinas, Roopa Mehta, Paloma Almeda-Valdes, Omar Yaxmehen Bello-Chavolla, Ivette Cruz-Bautista |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Intra-Abdominal Fat Adolescent 030209 endocrinology & metabolism Primary care Type 2 diabetes Critical Care and Intensive Care Medicine Models Biological Body Mass Index 03 medical and health sciences Young Adult 0302 clinical medicine Adipokines Metabolic Diseases Cardio metabolic Internal medicine medicine Humans Visceral fat Aged 030109 nutrition & dietetics Nutrition and Dietetics business.industry Middle Aged medicine.disease Obesity Cardiovascular Diseases Cohort Female Metabolic syndrome business |
| Zdroj: | Clinical nutrition (Edinburgh, Scotland). 39(5) |
| ISSN: | 1532-1983 |
| Popis: | Summary Background & aims Intra-abdominal and visceral fat (VAT) are risk factors for the development of cardio-metabolic comorbidities; however its clinical assessment is limited by technology and required expertise for its assessment. We aimed to develop a novel score (METS-VF) to estimate VAT by combining the non-insulin-based METS-IR index, waist-height ratio (WHtr), age and sex. Methods We developed METS-VF in a sample of 366 individuals with Dual X-ray absorptiometry (DXA). METS-VF was modeled using non-linear regression and validated in two replication cohorts with DXA (n = 184, with n = 118 who also had MRI) and bio-electrical impedance (n = 991). We also assessed METS-VF to predict incident type 2 diabetes (T2D) and arterial hypertension independent of body-mass index (BMI) in our Metabolic Syndrome Cohort (n = 6144). Results We defined METS-VF as: 4.466 + 0.011*(Ln(METS-IR))3 + 3.239*(Ln(WHtr))3 + 0.319*(Sex) + 0.594*(Ln(Age)). METS-VF showed better performance compared to other VAT surrogates using either DXA (AUC 0.896 95% CI 0.847–0.945) or MRI (AUC 0.842 95% CI 0.771–0.913) as gold standards. We identified a METS-VF cut-off point >7.18 in healthy patients which has 100% sensitivity (95% CI 76.8–100) and 87.2% specificity (95% CI 79.1–93.0) to identify increased VAT (>100 cm2). METS-VF also had adequate performance in subjects with metabolically-healthy obesity. Finally, in our metabolic syndrome cohort, subjects in the upper quintiles of METS-VF (>7.2) had 3.8 and 2.0-fold higher risk of incident T2D and hypertension, respectively (p Conclusion METS-VF is a novel surrogate to estimate VAT, which has better performance compared to other surrogate VAT indexes and is predictive of incident T2D and hypertension. METS-VF could be a useful tool to assess cardio-metabolic risk in primary care practice and research settings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect